The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
< 0.100 Eu/µg
The biological activity of this product was determined by its inhibitory effect of IL-8 production in human PBMC by Human sTRAIL/Apo2L.
95% inhibition (100ng/ml of sTRAIL/Apo2L) was reached using a concentration of 100ng/ml of sTRAIL Receptor-1.
Concentration information loading...
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
RECONSTITUTE with 60ul sterile WATER.
Cytotoxic TRAIL receptor
Death receptor 4
NF related apoptosis-inducing ligand receptor 1
TNF receptor superfamily member 10a
TNF-related apoptosis-inducing ligand receptor 1
TRAIL receptor 1
Tumor necrosis factor receptor superfamily member 10A
Tumor necrosis factor receptor superfamily member 10a variant 2
Tumor necrosis factor receptor superfamily, member 10a
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells.
Contains 1 death domain. Contains 3 TNFR-Cys repeats.